Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, today released a new video featuring Mr. John Sutcliffe, Consultant Spinal Neurosurgeon at The London Clinic, discussing his experience with Nociscan for evaluating chronic low back pain. The video is available here. To date, nearly 100 Nociscans have been conducted at The London Clinic, reflecting sustained physician engagement and growing integration into routine clinical practice.
Mr. Sutcliffe, who also serves as Lead Clinician at The London Spine Clinic, has over 30 years of experience treating spinal conditions. In the video, he notes that Nociscan “provides an additional layer of insight that complements traditional imaging,” adding that “having more objective data can help inform clinical decisions and improve confidence when evaluating patients with chronic low back pain.” Nociscan is a non-invasive solution that uses MR spectroscopy and proprietary signal processing to identify chemical biomarkers associated with disc pain, helping physicians differentiate between painful and non-painful discs in the lumbar spine.
Brent Ness, Chief Executive Officer of Aclarion, stated, “Approaching 100 scans at a leading international center like The London Clinic is an important indicator of increasing adoption and reinforces the potential for Nociscan to become a valuable tool in the evaluation of chronic low back pain.” Chronic low back pain affects approximately 266 million people worldwide, and when used alongside other diagnostic tools, clinical data has demonstrated up to a 97% surgical success rate when all Nociscan-positive discs are treated.
The continued use of Nociscan at The London Clinic highlights its potential to address a significant global healthcare challenge. For more information about Nociscan and to find a center, visit the company’s site map here.
